Delivery Order SPE2DR25D9367-SPE2DR26FKLG4
- Not listed
- The Defense Logistics Agency issued a $25,165.90 delivery order to DMS Pharmaceutical Group Inc. on April 29, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 15 MG tablets (60-count units). PPV-G GEN V is a single-award indefinite delivery contract through which the Defense Logistics Agency authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on April 30, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets. PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide. The parent contract SPE2DX carries a $499.999 billion ceiling...
- The Defense Logistics Agency issued a $37,989.81 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on May 5, 2026, for JAKAFI 10 mg tablets (60-count) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a single-award indefinite delivery contract with a $499.999 billion ceiling supporting pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical is the...
- The Defense Logistics Agency issued a $25,165.90 delivery order to DMS Pharmaceutical Group Inc. on May 6, 2026, for JAKAFI 15 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December 31, 2036, supporting pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide....
- The Defense Logistics Agency issued a $12,720.92 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on May 5, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 5 mg tablets (60-count units). PPV-G GEN V is DLA's single-award indefinite delivery contract supporting pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide. The underlying IDC, awarded November 13, 2025,...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on April 22, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count units), with an ultimate completion date of April 23, 2026. PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036, structured with a 30-month base period and three 30-month option...
- The Defense Logistics Agency issued a $50,883.68 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on May 1, 2026, for JAKAFI 5 mg tablets (60-count) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables supporting Department of...
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military...
- The Defense Logistics Agency issued a $16,526.95 delivery order to DMS Pharmaceutical Group Inc. on March 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business...
- The Defense Logistics Agency issued a $37,989.81 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables to Department of Defense military healthcare...
- SPE2DR25D9367Indefinite Delivery Contract
- SPE2DR25D9367-SPE2DR26FKLG4Delivery Order
The Defense Logistics Agency issued a $37,748.85 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on May 8, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 15 mg tablets (60-count supply). Ultimate completion date is May 11, 2026. PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract ($499.999 billion ceiling through December 31, 2036) under which DMS Pharmaceutical operates as the sole regional prime vendor for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide. Place of performance is Park Ridge, IL. The order carries firm fixed pricing and no set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.7k | 5/7/26 |